Search details
1.
Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers.
Acta Oncol
; 58(11): 1634-1639, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31347936
2.
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
Clin Cancer Res
; 29(8): 1423-1428, 2023 04 14.
Article
in English
| MEDLINE | ID: mdl-36729110
3.
Multiplex SuperSelective PCR Assays for the Detection and Quantitation of Rare Somatic Mutations in Liquid Biopsies.
J Mol Diagn
; 24(3): 189-204, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34954118
4.
Tumor volume as a predictor of cell free DNA mutation detection in advanced non-small cell lung cancer.
Transl Lung Cancer Res
; 11(8): 1578-1590, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-36090640
5.
Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor.
JCO Precis Oncol
; 52021.
Article
in English
| MEDLINE | ID: mdl-34250388
6.
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib.
JCO Precis Oncol
; 52021.
Article
in English
| MEDLINE | ID: mdl-34250398
7.
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Nat Commun
; 12(1): 3697, 2021 06 17.
Article
in English
| MEDLINE | ID: mdl-34140482
8.
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
Clin Cancer Res
; 27(3): 799-806, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-33172896
9.
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.
Lung Cancer
; 159: 66-73, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34311346
10.
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
JAMA Oncol
; 6(7): 1048-1054, 2020 07 01.
Article
in English
| MEDLINE | ID: mdl-32463456
11.
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
J Natl Cancer Inst
; 111(6): 575-583, 2019 Jun 01.
Article
in English
| MEDLINE | ID: mdl-30496436
12.
Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Nat Commun
; 13(1): 5579, 2022 Sep 23.
Article
in English
| MEDLINE | ID: mdl-36151107
13.
Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73].
Lung Cancer
; 162: 210, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34625293
Results
1 -
13
de 13
1
Next >
>>